Treatment of nontuberculous mycobacterial pulmonary infection in the U.S. Bronchiectasis and NTM registry: Treatment patterns, adverse events, and adherence to ATS/IDSA treatment guidelines.

Among 1,038 participants with pulmonary Mycobacterium avium complex and 120 with Mycobacterium abscessus enrolled in the Bronchiectasis & NTM Research Registry, about half received guideline-based therapy in the 24 months prior to registry enrollment. Side effects occurred in 21% of therapy recipients, of which 33% discontinued therapy.